Subscribe

Psoriatic Arthritis

Patients from the Corrona registry, an independent, observational US registry housing data on patients with rheumatic diseases, were included in Dr Harrold and colleagues’ study if they had received a PsA diagnosis; had initiated therapy with a TNFi (ie, adalimumab, etanercept, golimumab, or infliximab) between October 1, 2002, and March 21, 2013; and were aged ≥18 years.

London, United Kingdom—An early-phase study of bimekizumab, a monoclonal antibody potently and selectively inhibiting interleukin (IL)-17A and IL-17F, demonstrated strong responses in skin and joints of patients with psoriatic arthritis. IL-17A and IL-17F, key proinflammatory cytokines, are overexpressed in psoriatic skin lesions, said Sophie Glatt, MD, UCB Celltech, Slough, United Kingdom, in an oral presentation at the 2016 European League Against Rheumatism Annual Congress.
London, United Kingdom—Ixekizu­mab (Taltz) achieved clinically significant improvement in the signs and symptoms of psoriatic arthritis (PsA), including arthritis, dactylitis, and enthesitis, as well as skin improvements, during a 28-week extension phase of a 24-week, double-blind, phase 3 trial called SPIRIT-P1 (totaling 52 weeks).
Researchers in a phase 2b study of clazakizumab suggest that this drug may become a new option for treatment of the musculoskeletal effects—but not necessarily skin lesions—associated with psoriatic arthritis (PsA). Treatment for patients with predominant musculoskeletal effects represents an unmet need.
Yet another benefit of weight loss! The loss of excessive weight aided by bariatric surgery appears to improve symptoms of psoriasis and psoriatic arthritis, according to a retrospective pilot study presented at the annual meeting of the American College of Rheumatology.
Secukinumab 300 mg and 150 mg given subcutaneously achieved significant and sustained reductions in the burden of psoriasis on skin and nails in patients with active psoriatic arthritis (PsA) in the phase 3 FUTURE 2 trial.
A study presented at the 2015 annual meeting of the International Society for Pharmaco­economics and Outcomes Research documented the steep risk in cost of treatment of psoriatic arthritis (PsA) with biologics.
According to a network meta-analysis and cost-per-responder (CPR) analysis presented at the recent Academy of Managed Care Pharmacy annual meeting, adalimumab was the most cost-effective biologic for the treatment of psoriatic arthritis (PsA) in terms of incremental CPR for 2 clinical efficacy measurements and at 2 time points, weeks 12 and 24.
The diagnosis and management of psoriatic arthritis (PsA) can be challenging. It is important to make the right diagnosis and to start treating PsA early to optimize outcomes and to reduce the social and economic burden of this disease.
The method used to administer medication to patients can also heavily impact their medication adherence, placing a lot of importance on the quality and clinical relevance of adherence measures.
Page 1 of 3
Results 1 - 10 of 30
  • American Health & Drug Benefits
  • Lynx CME
  • Value-Based Care in Myeloma
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology